Skip to main content

Table 3 Dose and duration of analgesic use and risk of ESRD: All analgesics.

From: Analgesics use and ESRD in younger age: a case-control study

  

Short duration

Long Duration

  

Cases/controls

OR (95% CI)*

Cases/controls

OR (95% CI) *

Low dose

All analgesics

123/580

0.78 (0.63–0.97)

36/216

0.62 (0.43–0.89)

 

All monos together1

106/529

0.74 (0.59–0.93)

31/200

0.57 (0.39–0.85)

 

All combis together2

49/264

0.69 (0.50–0.95)

19/84

0.84 (0.51–1.40)

High Dose

All analgesics

70/214

1.21 (0.91–1.61)

132/582

0.84(0.67–1.05)

 

All monos together1

60/194

1.14 (0.84–1.55)

117/531

0.82(0.65–1.03)

 

All combis together2

29/88

1.22 (0.79–1.88)

71/268

0.99 (0.74–1.33)

  1. 1 Cases and controls that never used mono-analgesics were not shown in this table (47 cases, 138 controls for the group "all monos"
  2. 2 Cases and controls that never used combination-analgesics were not shown in this table (193 cases, 888 controls for the group "all combis"
  3. Unmatched analysis; index date 3 (5 years before start of dialysis); adjusted odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age, sex, country.
  4. The cut-off point for higher/lower use and shorter/longer duration is the respective median found in controls; compared with the standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) as referent (= 1.0): 546 cases and 2030 controls.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us